Clinical characteristics of 4490 COVID-19 patients in Africa: A meta-analysis

INTRODUCTION

A disease that was first reported in early December 2019¹ has led to a pandemic in 2020 that has resulted in about 39 million cases and over 1.1 million deaths as of 18th October, 2020². Nearly every continent of the earth, except Antarctica, has felt the impact of the novel Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)^3,4. It was predicted that Africa will be the worst hit with the pandemic, having no less than 223 million cases and more than 150,000 fatalities^3,5. However, eight months into the pandemic, this is not the case. The WHO African Region, comprising only 47 member states on the continent (without Djibouti, Egypt, Libya, Morocco, Somalia, Sudan and Tunisia), has reported only 3.2% of all COVID-19 cases (1,259,192 out of 39,596,858) and 2.6% of deaths (28,313 out of 1,107,374) globally as of October 18^th, 2020^2,6.

Nevertheless, to improve our understanding and management of this novel disease, it remains pertinent to define and analyze the clinical characteristics and outcomes of the disease in patients⁷. Several studies have described the clinical and epidemiological characteristics, risk factors, case management, and associated outcomes of different patient cohorts with COVID- 19 globally^1,7–15. Clinical features, diagnosis and treatment of COVID-19 have also been reviewed elsewhere¹⁶. However, there is limited information on the clinical characteristics of COVID-19 in patients in Africa. In this article, we describe a meta-analysis of the clinical characteristics of COVID-19 patients in Africa.

METHODOLOGY

Search databases and search strategyy

PubMed, Google scholar, Scopus, The Cochrane Library, EMBASE, and Africa journal online (AJOL) were electronically searched to collect clinical studies on the clinical characteristics of COVID-19 from January 1, 2020 to October 6, 2020. We also performed a manual search of the reference lists of included studies to avoid omitting any eligible study. Only studies written in English language and published online were included. The following terms were used in search alone OR in combination: “Coronavirus”OR“2019-nCoV”OR“COVID-19”OR“SARS-CoV-2” AND “Africa” OR “Comoros” OR “Djibouti” OR “Madagascar” OR “Malawi” OR “Seychelles” OR “Cameroon” OR “Central African Republic” OR “Chad” OR “Congo” OR “Equatorial Guinea” OR “Atlantic Islands” OR “Gabon” OR “Morocco” OR “South Sudan” OR “Sudan” OR “Botswana” OR “Lesotho” OR “Swaziland” OR “Benin” OR “Burkina Faso” OR “Cape Verde” OR “Ghana” OR “Guinea” OR “Guinea-Bissau” OR “Mauritania” OR “Niger” OR “Senegal” OR “Sierra Leone” OR “Togo” OR “Burundi” OR “Eritrea” OR “Ethiopia” OR “Kenya” OR “Mozambique” OR “Rwanda” OR “Somalia” OR “Tanzania” OR “Uganda” OR “Zambia” OR “Zimbabwe” OR “Angola” OR “Algeria” OR “Egypt” OR “Tunisia” OR “Namibia” OR “South Africa” OR “Gambia” OR “Liberia” OR “Mali” OR “Nigeria” AND English[lang]. Figure 1 shows the flow chart of the literature screening process.

• Download figure
• Open in new tab

Figure 1: Flow chart of the literature screening process

RESULTS

Gender distribution

The random effect model was used in the meta-analysis. Gender distribution showed that the proportion of male was 68.8% (95% CI, 64.6%-72.9%) with significant heterogeneity I² = 65.16%, p = 0.014 (Figure 2).

• Download figure
• Open in new tab

Figure 2: Proportion of males in COVID-19 patients

Fatality rate

The fatality rate in the 4490 patients included in the meta-analysis was 5.6% (95% CL, 2.7%- 8.6%) with significant heterogeneity (I²=85.9%, p= <0.001) (Figure 3).

• Download figure
• Open in new tab

Figure 3: Proportion of death rate in COVID-19 patients examined

DISCUSSION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is a positive-stranded single-stranded RNA virus within the β-coronavirus cluster¹¹. Humans have experienced two prior outbreaks of coronavirus infections - Severe Acute Respiratory Syndrome (SARS) in 2002, and Middle East Respiratory Syndrome (MERS) in 2012, all within the past 2 decades²³. Since the outbreak of COVID-19 in china, and the first infection record on African soil, identifying the clinical characteristics and its dynamics in COVID-19 patients has been the key effort of most clinical studies. In this study, we evaluated evidence from previous studies in Africa and conducted this meta-analysis to systematically review the clinical characteristics of COVID-19 patients on the continent between June 1 and October 2, 2020. Our analysis included 4490 COVID-19 patients from seven studies conducted in five countries (Morocco, Senegal, Uganda, Congo and Nigeria). To the best of our knowledge,this is the first description and analysis of the clinical characteristics of COVID-19 patients in Africa.

From our analysis, males were the most affected subjects. This finding agrees with the finding of several studies conducted on other continents such as China^{1,10,11,13,14}, Kuwait⁷, and the United States¹². Although, during the SARS-CoV pandemic in 2002, there was a female dominance²⁴, and in a study of 869 patients confirmed with COVID-19 in Wuhan, China, there were less men (43.4%)¹³. The most common symptoms of patients with COVID-19 encountered were fever, cough, breathing problem and headache, while diarrhea and rhinorrhea were least encountered. Fever as a clinical symptom of SARS-CoV-2 infection has been found to be associated with other previous coronaviruses infections as documented by SARS-CoV, MERS-CoV, and SARS-CoV-2^24,25. Our findings of fever, cough and breathing problems as clinical symptoms of COVID-19 were in tandem with the findings of other studies, with up to 99% of patients experiencing fever²⁴. However, the proportion of patients that developed fever in our analysis was lower than the reported from meta-analysis done in China and other countries where over 80% of the patients examined had fever^1,10,12,26. Our study also reported low proportion in cough and breathing problems as compared with studies done outside Africa^11,12. The case fatality rate from the analyzed data for COVID-19 patients in Africa was lower than reported in other studies,^10,12,14 but was higher than reports reviewed by Zhu et al.²⁴ and Rodriguez-Morales et al.²⁷

This study is not without its strengths and weaknesses. The strengths of this study include its large sample size and the high-quality score of studies included in the analysis. Some limitations were also conducting our meta-analysis. First, most studies included studies were retrospective and conducted at single centers. This may have introduced admission bias and selection bias, so we cannot rule out the influence of other confounding factors. The sample sizes for two studies^9,18 were relatively small, so the test efficiency may be insufficient. Also, data collected in most of the included studies did not include laboratory findings, hence, it was difficult to analyze the clinicopathological characteristics of the disease in patients across Africa. This meta-analysis showed a significant heterogeneity between the studies, due to too many outcomes, and there was no subgroup analysis, which could affect the accuracy of the results presented.

CONCLUSION

Currently, documented evidence shows that the most commonly encountered symptoms of COVID-19 patients in Africa were fever, cough, breathing problem and headache. The case-fatality was low, contrary to predictions and modeling results by experts. More high-quality prospective studies are required to verify the above conclusions and to gain more insights into the clinical characteristics of COVID-19 patients in Africa. However, in the absence of any vaccine, relevant measures such as those that address infectious disease outbreak response²⁸ should be put in place to slow down the spread of the virus.

Consent for Publishing

All authors gave their consent for publishing

Availability of Supporting Data

Besides those presented in the study, there are no other supporting data for this manuscript.

Competing Interests

All authors declare no competing interests.

Funding

None

Authors’ contributions

TJO and LIU were both involved in the conceptualization, design, analysis, and writing of the manuscript. Both authors approved the final draft of the manuscript.